|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8969336||ASTELLAS||Diamino heterocyclic carboxamide compound|| |
(7 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9487491||ASTELLAS||Diamino heterocyclic carboxamide compound|| |
(6 years from now)
|US10786500||ASTELLAS||Stable pharmaceutical composition for oral administration|| |
(12 years from now)
Xospata is owned by Astellas.
Xospata contains Gilteritinib Fumarate.
Xospata has a total of 3 drug patents out of which 0 drug patents have expired.
Xospata was authorised for market use on 28 November, 2018.
Xospata is available in tablet;oral dosage forms.
Xospata can be used as treatment of acute myeloid leukemia (aml).
Drug patent challenges can be filed against Xospata from 2022-11-28.
The generics of Xospata are possible to be released after 01 July, 2036.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Orphan Drug Exclusivity (ODE)||Nov 28, 2025|
|New Chemical Entity Exclusivity (NCE)||Nov 28, 2023|
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic